La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb.
After seeing its reputation as a leader in multiple sclerosis erode over recent years, Merck KGaA has decided to carve back the number of staffers working in preclinical R&D in the field.
Dogs with spontaneously occurring, highly aggressive brain tumors such as glioblastoma multiforme have proven to be highly accurate models of human brain cancer. So when the owners of a 12-year-old mixed-breed dog with glioblastoma showed up at the Virginia-Maryland Regional College of Veterinary Medicine having exhausted all other treatment options, they agreed to try an experimental technology called nonthermal irreversible electroporation.
PARIS-- Paris-based Cellectis has followed through with plans for an IPO in the U.S., filing Friday to raise $115 million in the hot American market as it pushes ahead on CAR-T research.
Sanofi has made official what's no longer news, trotting out Olivier Brandicourt as its next chief executive. Stepping in on April 2, the experienced Frenchman inherits a wealth of commercial challenges, a quixotic relationship with local regulators and a make-or-break pipeline the company believes can bring in $38 billion over 5 years.
Cerecor acquired the rights to an Eli Lilly antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders.
AstraZeneca has struck a deal with BioData to use Labguru across its preclinical R&D sites. The deal will see AstraZeneca phase out its current patchwork of legacy systems in favor of BioData's web-based lab management system.
Jaguar Animal Health announced Thursday that during a pilot study of its treatment Canalevia to treat diarrhea, 91% of dogs who received the drug responded positively to it, vs. 50% of dogs who were given a placebo.
Startup Beta-O2 Technologies already has a bioartificial pancreas in a tiny three-person clinical trial. Now, it has preclinical data for its next device that uses the same implantable bioreactor technology with a new cell type--the βAir Bio-artificial Adrenal system.
Eli Lilly says it will extend the massive Phase III trial for its highly anticipated drug candidate evacetrapib, a CETP inhibitor that works to lower LDL, or "bad," cholesterol levels and raise HDL, or "good," cholesterol levels, by 6 months.